Mourey F, Sureja V, Kheni D, et al. - In this randomized, double-blind, placebo-controlled trial, researchers tested the safety and effectiveness of Saccharomyces cerevisiae variant boulardii CNCM I-3799 (S. boulardii CNCM I-3799) in the management of acute diarrhea in children. According to the World Health Organization guidelines on the management of acute diarrhea in children, a total of 100 infants and children 3–36 months of age with acute diarrhea received medical care and were randomly assigned to the probiotic group (S. boulardii CNCM I-3799 at a daily dose of 5 billion CFU twice daily) or to the placebo group. The administration of S. boulardii CNCM I-3799 has been correlated with beneficial effects on duration and severity of diarrhea. S. boulardii CNCM I-3799 supplementation in children with acute diarrhea has been shown to be efficacious in decreasing the duration and severity of diarrhea in infants and children.